Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Instituto de investigación eslovaco que ha desarrollado un sistema único de aislamiento in vivo de células tumorales circulantes de sangre periférica busca licenciatarios o inversores

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOSK20181029001
Publicado:
19/11/2018
Caducidad:
20/11/2019
Resumen:
Un instituto de investigación y una universidad de Eslovaquia han desarrollado un sistema único de aislamiento in vivo de células tumorales circulantes de sangre periférica. Este sistema permite el aislamiento de las CTC en todo el volumen de sangre sin que esta abandone el torrente sanguíneo. La tecnología aprovecha las nanopartículas magnéticas revestidas con un anticuerpo monoclonal que se inyectan en el torrente sanguíneo por vía intravenosa, así como un cable especial que contiene un núcleo magnético revestido con una capa no magnética. El instituto de investigación busca un licenciatario o inversor especializados en diagnóstico del cáncer y medicina personalizada.

Details

Tittle:
An established Slovak research institute has developed a unique system for in vivo isolation of circulating tumour cells from peripheral blood and is looking for licensees or investors
Summary:
An established Slovak scientific and research institute in cooperation with a traditional Slovak university have developed a unique system for in vivo isolation of circulating tumour cells from peripheral blood.
The system allows repeated CTCs (circulating tumour cells) isolation from the whole blood volume without blood leaving the bloodstream or sampling it. They are looking for licensee or investor partners from the industry, dealing with cancer diagnostics and personalised medicine.
Description:
Each tumour releases cells into the patient´s blood or lymphatic system which subsequently enter various parts of the body, creating secondary tumour deposits - metastases. These cells are called circulating tumour cells (CTCs). Their detection in blood has prognostic significance and also allows observing changes in tumour properties in real time.

Due to a very low amount of CTCs in the blood, the biological and clinical knowledge of CTCs are strongly dependent on isolation parameters and the technology used to increase the detection success. Existing methods for CTCs detection do not allow a detailed characterization of CTCs, as the amount of isolated CTCs is usually very small.

A team of inventors from the Slovak research institute in cooperation with Slovak university has developed a unique system for in vivo isolation of circulating tumour cells from peripheral blood. The institute was established in 1953 in order to carry out fundamental and applied research and new developments in the field of civil engineering and architecture. The university which was engaged in the development process belongs to well-known university with the strong expertise in biotech.

This innovative technology takes advantage of magnetic nanoparticles coated with a monoclonal antibody that are injected into the bloodstream via an intravenous cannula, as well as of a special wire containing a magnetic core coated with a non-magnetic mantle.

The principle of isolation of circulating cells from peripheral blood according to this unique solution is as follows:
Magnetic nanoparticles coated with a monoclonal antibody are injected into the vein through a venous cannula, while their position is controlled using magnets. The nanoparticles are exposed to circulating tumour cells. After in vivo incubation the nanoparticles are moved closer to the venous cannula by the movement of large magnets and a special wire comprising a magnetic core coated with a non-magnetic mantle is inserted through the cannula into the blood stream. Large magnets are removed and nanoparticles are attracted by the magnetic wire. Magnetic wire coated with nanoparticles with attached CTCs is removed from the cannula and placed in a test tube with a suitable medium. The magnetic core is removed and the nanoparticles with attached CTCs are released into the medium for further analysis.

The research institute is looking for partners to cooperate with via license agreement (the Slovak research institute is looking for licensees) or via financial agreement (an investor is sought).
Advantages and Innovations:
Competitive advantages:
- In vivo isolation of CTCs and/or CSCs (cancer stem cell)
- Isolation of CTCs and/or CSCs from the whole volume of patient´s blood
- Detection of CTCs and/or CSCs in very low concentrations
- More effective than available solutions
- Universal solution that may be adapted to any type of blood cells
- Easy and straightforward manipulation

Its biggest advantage over existing solutions lies especially in the fact, that this system makes it possible to isolate more CTCs (or other cells present in peripheral blood) than other methods.
Stage of Development:
Concept stage
IPs:
Patents granted
CommeR Statunts Regarding IPR Status:
- Granted European patent validated in Germany and France
- Granted Slovak patent

Partner sought

Type and Role of Partner Sought:
Type: company (industry)

Field of activity: especially molecular diagnostics of cancer and personalized medicine.

Role: License agreement - the Slovak research institute is looking for licensees
Financial agreement - an investor into this technology is sought.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German
Slovak

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06001011 Enfermedades circulatorias y del corazón
06001019 Tecnologías de células madre